CJC-1295 NO DAC + Ipamorelin 5 5
CJC-1295 NO DAC + Ipamorelin 5 5
CJC-1295 NO DAC + Ipamorelin 5 / 5
The combination of CJC-1295 (a growth hormone-releasing peptide) without the drug-affinity component (DAC) and Ipamorelin offers a synergistic approach to stimulating endogenous growth hormone release. Both peptides are administered in equal amounts—5 mg each per cycle—to achieve balanced stimulation while minimizing side effects that can arise from overstimulation of the pituitary gland.
CJC-1295 NO DAC / IPAMORELIN Structure
CJC-1295 NO DAC is a linear peptide composed of 44 amino acids, engineered to bind and activate the growth hormone secretagogue receptor (GHS-R). Removing the DAC shortens its half-life compared to the DAC-containing variant, enabling more frequent dosing without prolonged suppression. Ipamorelin is a hexapeptide (His–Pro–Trp–Thr–Leu–NH₂) that selectively targets the same receptor with high affinity and minimal prolactin release. The structural compatibility of these two peptides allows them to be mixed in solution without steric hindrance, preserving their individual bioactivities.
Additional Information
The 5 mg/5 mg dosage schedule is commonly used for body recomposition protocols. Users report increased lean muscle mass, improved recovery times, and reduced visceral fat after several weeks of consistent use. Monitoring serum growth hormone levels can help tailor the regimen, ensuring that peak concentrations remain within therapeutic ranges.
Peptide Storage
To maintain potency:
Store both peptides at 2 °C to 8 °C (refrigerated) when not in use.
Keep frozen samples below –20 °C; thaw only once before re-injection.
Protect from light by using opaque vials or wrapping containers with foil.
CJC-1295 NO DAC + Ipamorelin 5 5
CJC-1295 NO DAC + Ipamorelin 5 / 5
The combination of CJC-1295 (a growth hormone-releasing peptide) without the drug-affinity component (DAC) and Ipamorelin offers a synergistic approach to stimulating endogenous growth hormone release. Both peptides are administered in equal amounts—5 mg each per cycle—to achieve balanced stimulation while minimizing side effects that can arise from overstimulation of the pituitary gland.
CJC-1295 NO DAC / IPAMORELIN Structure
CJC-1295 NO DAC is a linear peptide composed of 44 amino acids, engineered to bind and activate the growth hormone secretagogue receptor (GHS-R). Removing the DAC shortens its half-life compared to the DAC-containing variant, enabling more frequent dosing without prolonged suppression. Ipamorelin is a hexapeptide (His–Pro–Trp–Thr–Leu–NH₂) that selectively targets the same receptor with high affinity and minimal prolactin release. The structural compatibility of these two peptides allows them to be mixed in solution without steric hindrance, preserving their individual bioactivities.
Additional Information
The 5 mg/5 mg dosage schedule is commonly used for body recomposition protocols. Users report increased lean muscle mass, improved recovery times, and reduced visceral fat after several weeks of consistent use. Monitoring serum growth hormone levels can help tailor the regimen, ensuring that peak concentrations remain within therapeutic ranges.
Peptide Storage
To maintain potency:
Store both peptides at 2 °C to 8 °C (refrigerated) when not in use.
Keep frozen samples below –20 °C; thaw only once before re-injection.
Protect from light by using opaque vials or wrapping containers with foil.